Basal Cell Carcinoma Treatment Market Analysis

Basal Cell Carcinoma Treatment Market Analysis

To get key market trends

  Download Free Sample

Based on treatment type, the market is segmented into surgery, medication, other treatment types. The surgery segment dominated the market with USD 3.5 billion in 2023.
 

• Surgical treatments including Mohs micrographic surgery are renowned for its high success rates. For instance, according to the Skin Cancer Foundation, the cure rate for new skin cancers treated with Mohs surgery is up to 99%. These procedures ensure complete removal of cancerous tissues with significantly reducing the chances of recurrence.
   
• Thus, surgery is preferrable and can be effectively employed for various sizes and types of BCCs, including those located in challenging areas such as the face. Such factors will augment the segmental growth in the coming years as well.
   
• Further, continuous advancements in surgical technologies enhance the safety, precision, and effectiveness of these treatments, thereby increasing their attractiveness to both patients and healthcare providers which in turn will boost the industry growth.
   

Based on cancer type, the basal cell carcinoma treatment market is divided into nodular, superficial spreading, sclerosing, and pigmented. The nodular segment accounted for significant market share of 66.5% in 2023.
 

• Nodular basal cell carcinoma (NBCC) typically presents as a noticeable nodule on the skin, making it easier to detect and diagnose early compared to other skin cancer subtypes that might be less visible or more aggressive.
   
• Also, early detection results in a higher number of diagnosed cases contribute to its prevalence. For instance, according to National Center for Biotechnology Information (NCBI), nodular basal cell carcinoma comprises about 60-80% of the skin cancers cases and occurs most often on the skin of the head. Thus, growing prevalence of NBCC among geriatric population will spur the segmental growth.
   

North America basal cell carcinoma treatment market is expected to grow at 8.3%, to reach USD 5.6 billion by the end of 2032.
 

• Basal cell carcinoma is the most common type of skin cancer in North America, accounting for a substantial portion of all diagnosed cases among BCC disease. For instance, according to American Cancer Society report, about 4 million basal and squamous cell skin cancers are diagnosed each year in the U.S.
   
• Thus, increasing incidence of such disease among aging population demographics, coupled with heightened awareness of skin cancer risks will supplement the country level market growth. Furthermore, the region boasts a well-established healthcare infrastructure, including numerous cancer hospitals and clinics equipped with advanced medical technologies.
   

The UK BCC treatment market is experiencing robust growth in European market.
 

• The incidence of basal cell carcinoma (BCC) in the UK has seen a notable increase over recent years. For instance, according to NHS Digital data released as part of the National Disease Registration Service (NDRS) Get Data Out (GDO) programme, there were 158,934 BCC cases in 2019, up from 128,406 in 2013. This surge implicates the growing demand for effective treatment solutions and presents significant opportunities within the UK BCC treatment market.  
   

The Asia Pacific BCC treatment market is witnessing substantial growth of 9.2% during the analysis period.
 

• The regional growth can be attributed to early detection of the disease which will influence the adoption trend for different treatment option. Also, the early detection not only increases the likelihood of successful treatment outcomes but also reduces the need for more invasive procedures, which can be expensive and more burdensome for patients especially in middle- and low-income economies. Thus, the integration of these advanced diagnostic tools into routine clinical practice is expected to contribute to the overall expansion of the BCC treatment market.